Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $276.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target upped by JPMorgan Chase & Co. from $265.00 to $276.00 in a report issued on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of several other reports. Raymond James Financial reiterated an “outperform” rating and issued a $239.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Stifel Nicolaus set a $275.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday. Needham & Company LLC upped their target price on shares of Jazz Pharmaceuticals from $282.00 to $292.00 and gave the company a “buy” rating in a report on Tuesday. Leerink Partners upped their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Finally, Canaccord Genuity Group initiated coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $290.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $272.74.

Jazz Pharmaceuticals Trading Down 1.9%

NASDAQ:JAZZ opened at $256.65 on Tuesday. Jazz Pharmaceuticals has a 1 year low of $106.65 and a 1 year high of $265.05. The stock has a market cap of $16.66 billion, a P/E ratio of 17.70, a P/E/G ratio of 0.23 and a beta of 0.32. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.85 and a current ratio of 1.78. The stock has a 50-day simple moving average of $240.89 and a 200-day simple moving average of $209.19.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.Jazz Pharmaceuticals’s revenue was up 15.5% on a year-over-year basis. During the same period last year, the business posted ($8.25) EPS. As a group, analysts anticipate that Jazz Pharmaceuticals will post 21.61 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total transaction of $662,143.37. Following the completion of the sale, the director directly owned 9,567 shares of the company’s stock, valued at $2,311,100.19. This represents a 22.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $252.98, for a total value of $1,517,880.00. Following the sale, the director directly owned 360,682 shares of the company’s stock, valued at $91,245,332.36. The trade was a 1.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 19,098 shares of company stock valued at $4,649,786. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Royal Bank of Canada grew its position in Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after buying an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after buying an additional 209,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Jazz Pharmaceuticals by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock worth $24,479,000 after acquiring an additional 7,954 shares during the period. Focus Partners Wealth lifted its stake in shares of Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after acquiring an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo upgraded Jazz Pharmaceuticals to Buy and raised its price target to $300 from $285, adding to a broadly favorable analyst view. Jazz Pharmaceuticals Receives a Buy from Wells Fargo
• Positive Sentiment: Morgan Stanley raised its price target to $280, while Needham also forecast meaningful appreciation and maintained a bullish stance. JPMorgan separately indicated that the stock could rise, reinforcing investor confidence in JAZZ’s valuation and growth prospects. Morgan Stanley Boosts Jazz Pharmaceuticals Price Target
• Positive Sentiment: Jazz’s second-quarter revenue reached $1.21 billion, exceeding the $1.11 billion consensus estimate and increasing 15.5% year over year. Management raised its 2026 revenue guidance to $4.60 billion-$4.75 billion, supported by strength in its neuroscience and oncology businesses.
• Positive Sentiment: The Xywav-led oxybate franchise continues to post double-digit growth despite generic Xyrem competition, reducing concerns about near-term erosion in Jazz’s core business. Potential FDA approval of Ziihera for first-line gastroesophageal cancer on August 25 also provides an additional catalyst.
• Neutral Sentiment: A valuation comparison with Techne highlights JAZZ as a stock investors are assessing on earnings, growth and relative value metrics, but the article does not represent a new fundamental development for Jazz Pharmaceuticals. JAZZ vs. TECH Which Stock Is the Better Value Option
• Negative Sentiment: Adjusted quarterly EPS of $5.71 missed the $6.18 consensus estimate, which could limit upside if future earnings do not keep pace with revenue growth.
• Negative Sentiment: Director Bruce Cozadd sold 6,000 shares worth about $1.52 million under a pre-arranged Rule 10b5-1 plan. The sale reduced his holdings by only 1.64%, making it a limited signal of insider concern.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.